A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.

Study Overview

• Status: Recruiting
• Conditions: Chronic Hepatitis D Infection
• Intervention / Treatment: Drug: Bulevirtide (BLV)

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Gilead Clinical Study Information Center; Phone Number: 1-833-445-3230 (GILEAD-0); Email: GileadClinicalTrials@gilead.com

Study Locations

• United States
  • Florida
    • Edgewater, Florida, United States, 32132
      • Recruiting
      • Velocity Clinical Research, New Smyrna Beach
    • Miami, Florida, United States, 33014
      • Recruiting
      • Clinical Pharmacology of Miami, LLC
    • Miami, Florida, United States, 33147
      • Recruiting
      • Advanced Pharma CR, LLC
    • Miami Lakes, Florida, United States, 33014
      • Recruiting
      • Panax Clinical Research
    • Miami Lakes, Florida, United States, 33016
      • Recruiting
      • Floridian Clinical Research, LLC
    • Saint Petersburg, Florida, United States, 33705
      • Recruiting
      • Global Clinical Professionals Research
    • Tampa, Florida, United States, 33603
      • Recruiting
      • Genesis Clinical Research, LLC
  • Minnesota
    • Saint Paul, Minnesota, United States, 55114
      • Recruiting
      • Nucleus Network

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Key Inclusion Criteria:

All Individuals:

• Body mass index (BMI) of at least ≥ 18.0 kg/m^2 and ≤ 40.0 kg/m^2 at screening.
• No clinically significant abnormalities on electrocardiogram (ECG)
• No known Liver Disease (Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)) ≤ 3 x upper limit of normal (ULN) at screening.

Individuals with Renal Impairment (RI):

• Have RI classification at screening that has been unchanged during the 90 days prior to study drug dosing.

• Estimated Glomerular Filtration Rate (eGFR) must be the following (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Inker 2021)) based on serum creatinine as measured at the screening evaluation:

  • Severe RI (Groups A and B): eGFR ≥ 15 to ≤ 29 mL/min/1.73 m^2
  • Moderate RI (Group C): eGFR ≥ 30 to ≤ 59 mL/min/1.73 m^2
  • Mild RI (Group D): eGFR ≥ 60 to ≤ 89 mL/min/1.73 m^2
• Hemoglobin ≥ 9 g/dL at screening.
• Individuals with cardiovascular disease, hypertension, diabetes mellitus, hyperlipidemia, hypothyroidism, osteoporosis, and many others) may be included provided that these diseases/conditions are clinically stable.

Matched Control Individuals:

• Have an eGFR of at least 90 mL/min/1.73 m^2 (using the CKD-EPI equation) based on serum creatinine as measured at screening evaluation.
• Matched for sex, age (± 10 years), and BMI (± 20%, 18.0 ≤ BMI ≤ 40.0 kg/m^2) with the respective participant in the RI group.

Key Exclusion Criteria:

All Individuals:

• Positive human immunodeficiency virus (HIV) test, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody with detectable HCV viral ribonucleic acid (RNA) at screening.
• Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with participant treatment, assessment, or compliance with the protocol.

Individuals with RI:

• Recent history of reception of any blood or blood products or history of major bleeding within 4 weeks of dosing.
• Positive test for drugs of abuse, including alcohol at screening or admission, with the exception of opioids and tetrahydrocannabinol (THC, marijuana) under prescription and verified by the investigator as for pain management.
• Received treatment with trimethoprim or cimetidine or tenofovir prodrugs (tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)) (affects elimination of creatinine) or with competitors of renal tubular excretion (eg, probenecid, chronic high-dose nonsteroidal anti-inflammatory drugs) within 28 days of Day -1.
• Received known nephrotoxic drugs (eg, aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, cyclosporine, tacrolimus, herbal remedies (eg, compounds with aristolochic acid)) within 28 days of Day -1.
• Individuals requiring or anticipated to require dialysis within 90 days of study entry.
• Serum albumin concentration <25 g/L.
• Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg).

Matched Control Individuals:

• Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A: Bulevirtide (BLV), Severe Renal Impaired Participants; Participants with severe renal impairment will receive BLV 2 mg once daily for 6 days. Following completion and evaluation of pharmacokinetics (PK) and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated.	Drug: Bulevirtide (BLV); Administered via subcutaneous (SC) injections; Other Names: Myrcludex B; Hepcludex®
Experimental: Group A: BLV, Normal Renal Function (Matched Control Participants); Participants with normal renal function will receive BLV 2 mg once daily for 6 days. Following completion and evaluation of PK and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated.	Drug: Bulevirtide (BLV); Administered via subcutaneous (SC) injections; Other Names: Myrcludex B; Hepcludex®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)	AUCtau is defined as area under the concentration versus time curve over the dosing interval at steady state.	Day 6: Predose up to 24 hours postdose
PK Parameter: Cmax ss of BLV	Cmax is defined as the maximum observed concentration of drug at steady state.	Day 6: Predose up to 24 hours postdose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK Parameter: AUC0-24 of BLV	AUC0-24 is defined as the concentration of drug over time between time 0 hour and time 24 hours.	Day 1: Predose up to 24 hours postdose
PK Parameter: Cmax of BLV	Cmax is defined as the maximum observed concentration of drug.	Day 1: Predose up to 24 hours postdose
PK Parameter: Tmax of BLV	Tmax is defined as the time (observed time point) of Cmax.	Day 1 and Day 6: Predose up to 24 hours postdose
PK Parameter: t1/2 of BLV	t1/2 is defined as the estimate of the terminal elimination half-life of the drug.	Day 1: Predose up to 24 hours postdose and Day 6: Predose up to 48 hours postdose
PK Parameter: CLss/F of BLV	CLss/F is defined as the apparent clearance at steady state.	Day 6: Predose up to 48 hours postdose
PK Parameter: Vss/F of BLV	Vss/F is defined as the apparent volume of distribution at steady state.	Day 6: Predose up to 48 hours postdose
PK Parameter: Ctrough of Total Bile Acids (BA)	Ctrough is defined as the concentration of total BA at the end of the dosing interval.	Day 2 and Day 5 (predose), Day 7, and Day 8
PK Parameter: Cmax of Total BA	Cmax is defined as the maximum observed concentration of total BA.	Day 1 and Day 6: Predose up to 24 hours postdose
PK Parameter: AUC0-24 of Total BA	AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours.	Day 1 and Day 6: Predose up to 24 hours postdose
PK Parameter: Tmax of Total BA	Tmax is defined as the time (observed time point) of Cmax of total BA.	Day 1 and Day 6: Predose up to 24 hours postdose
Percentage of Participants With Treatment-Emergent Adverse Events		First dose date up to 6 days plus 7 days
Percentage of Participants With Laboratory Abnormalities		First dose date up to 6 days plus 7 days

Collaborators and Investigators

• Sponsor: Gilead Sciences
• Investigators: Study Director: Gilead Study Director, Gilead Sciences

Publications and helpful links

Helpful Links

• Gilead Clinical Trials Website

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2023
• Primary Completion (Estimated): May 1, 2026
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: February 27, 2023
• First Submitted That Met QC Criteria: February 27, 2023
• First Posted (Actual): March 8, 2023

Study Record Updates

• Last Update Posted (Actual): March 15, 2024
• Last Update Submitted That Met QC Criteria: March 13, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; RNA Virus Infections; Virus Diseases; Infections; Kidney Diseases; Urologic Diseases; Disease Attributes; Liver Diseases; Hepatitis, Viral, Human; Hepatitis, Chronic; Hepatitis; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Hepatitis D; Hepatitis D, Chronic; Renal Insufficiency
• Other Study ID Numbers: GS-US-589-6160; 2022-502054-13-00 (Other Identifier: European Medicines Agency)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No